A Phase 3/4, Prospective, Randomized, Active Treatment-Controlled, Parallel-Design, Multicenter Study to Evaluate the Safety of DEXYCUfor the Treatment of Inflammation Following Ocular Surgery for Childhood Cataract
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
60
single anterior chamber injection
topical administration four times a day for 28 days, followed by treatment taper
EyePoint Investigational Site
Huntington Beach, California, United States
RECRUITINGEyePoint Investigational Site
Palo Alto, California, United States
ACTIVE_NOT_RECRUITINGEyePoint Investigative Site
Grade of anterior chamber cells (ACC)
Time frame: Post-Operative Day 14
Grade of anterior chamber flare (ACF)
Time frame: Post-Operative Day 14
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Boston, Massachusetts, United States
EyePoint Investigational Site
Jackson, Mississippi, United States
RECRUITINGEyePoint Investigational Site
Omaha, Nebraska, United States
RECRUITINGEyePoint Investigational Site
Buffalo, New York, United States
RECRUITINGEyePoint Investigative Site
New York, New York, United States
RECRUITINGEyePoint Investigational Site
Rochester, New York, United States
RECRUITINGEyePoint Investigational Site
Charleston, South Carolina, United States
RECRUITING